Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases
Public ClinicalTrials.gov record NCT00716066. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients With Autoimmune Neurologic Diseases
Study identification
- NCT ID
- NCT00716066
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Enrollment
- 53 participants
Conditions and interventions
Conditions
- Autoimmune Disease
- Autoimmune Nervous System Disorder
- Autologous Transplant Autoimmune
- CIDP Transplant
- Central Nervous System Vasculitis
- Cerebellar Degeneration
- Chronic Inflammatory Demyelinating Polyneuropathy
- HCT for Neurologic Autoimmune Disorders
- Lambert Eaton Myasthenic Syndrome
- MS Stem Cell Transplant
- Multiple Sclerosis Stem Cell Transplant
- Multiple Sclerosis Transplant
- Myasthenia Gravis
- Myasthenia Gravis Transplant
- Neurologic Autoimmune Disease
- Neuromyelitis Optica
- Opsoclonus Myoclonus Syndrome
- Rasmussen Subacute Encephalitis
- Stiff Person Syndrome
Interventions
- Anti-Thymocyte Globulin Biological
- Autologous Hematopoietic Stem Cell Transplantation Procedure
- Carmustine Drug
- Cytarabine Drug
- Etoposide Drug
- Laboratory Biomarker Analysis Other
- Melphalan Drug
- Peripheral Blood Stem Cell Transplantation Procedure
- Prednisone Drug
- Syngeneic Bone Marrow Transplantation Procedure
Biological · Procedure · Drug + 1 more
Eligibility (public fields only)
- Age range
- Up to 71 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2008
- Primary completion
- Dec 29, 2025
- Completion
- Jan 30, 2030
- Last update posted
- Feb 26, 2026
2008 – 2030
United States locations
- U.S. sites
- 3
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Colorado Blood Cancer Institute | Denver | Colorado | 80218 | — |
| Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington | 98109 | — |
| Swedish Medical Center-First Hill | Seattle | Washington | 98122-4307 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00716066, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 26, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00716066 live on ClinicalTrials.gov.